The Unholy Trinity of Weight Loss Drugs: A New Challenger Emerges A new player has entered the fray in the war on obesity, promising results that surpass those of its predecessors.
Retatrutide, a weight loss drug developed by Eli Lilly, completed a late stage trial with remarkable success. Patients taking the highest dose lost an average of 70.
3 pounds over 80 weeks, with over 45% shedding more than 30% of their body weight. This achievement is significant because losing 30% of one's body weight is often compared to the results of bariatric surgery.